Cargando…
Learning from the “tail end” of de-implementation: the case of chemical castration for localized prostate cancer
BACKGROUND: Men with prostate cancer are often treated with the suppression of testosterone through long-acting injectable drugs termed chemical castration or androgen deprivation therapy (ADT). In most cases, ADT is not an appropriate treatment for localized prostate cancer, indicating low-value ca...
Autores principales: | Skolarus, Ted A., Forman, Jane, Sparks, Jordan B., Metreger, Tabitha, Hawley, Sarah T., Caram, Megan V., Dossett, Lesly, Paniagua-Cruz, Alan, Makarov, Danil V., Leppert, John T., Shelton, Jeremy B., Stensland, Kristian D., Hollenbeck, Brent K., Shahinian, Vahakn, Sales, Anne E., Wittmann, Daniela A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555144/ https://www.ncbi.nlm.nih.gov/pubmed/34711274 http://dx.doi.org/10.1186/s43058-021-00224-8 |
Ejemplares similares
-
Correction: Learning from the “tail end” of de-implementation: the case of chemical castration for localized prostate cancer
por: Skolarus, Ted A., et al.
Publicado: (2023) -
De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)
por: Skolarus, Ted A., et al.
Publicado: (2018) -
Differential adoption of castration‐resistant prostate cancer treatment across facilities in a national healthcare system
por: Caram, Megan E. V., et al.
Publicado: (2023) -
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022) -
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial
por: Skolarus, Ted A., et al.
Publicado: (2017)